388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com

 CELLASTRA INC

DELIVERING THE GENETIC CODE TO THE WOUND FOR SCAR-LESS HEALING

 

TARGETING  GLOBAL UNMET NEEDS IN SURGERY, TRAUMA AND  BURN  INJURIES

CELLASTRA NEWS

CELLASTRA'S STRATEGIC REPORT 03 /11/2020:

TOP GENE THERAPY COMPANIES

LINK 

 

CELLASTRA INC 03/03/2020

Cellastra announces long-term results from in-vivo transgene expression of proprietary anti-scarring peptide

Preparing for clinical study in burn injuries

San Francisco, CA, March 3, 2020  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results  for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.

Cellastra recently reported results demonstrating that CELLEXA delivers the genetic code for the lactoferrin sub-peptide with the same amino acid sequence enabling expression during the first month of ovservation.

 “Our new results from long-term follow up demonstrates continued robust and durable transgenic expression and production of the peptide throughout the 11 week observation period  after intramuscular injection, and furthermore no adverse effects were noted” said Dr Karl Mettinger, MD, PhD, President & CEO of C

                                          READ MORE

02/19/2020

NEW GENE THERAPY INSTITUTE CREATE BY NIH

                                          READ MORE

INVESTOR PRESENTATION MARCH 2020  LINK

PRESS RELEASES

Cellastra announces results from in-vivo transgene expression of proprietary anti-scarring peptide.                             

Preparing for clinical study in burn injuries

San Francisco, CA, December 15, 2019  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results  for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.     

                                          READ MORE

CELLASTRA INC 07/15/2019

Cellastra announces filing of global patent application for prevention of scars and adhesions.

                                         READ MORE

CELLASTRA INC 06/24/2019

Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.

Preparing for clinical study in burn injuries

                                       READ MORE

CELLASTRA INC 04/04/2019

 

Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019

Prof. Folke Sjoberg, Cellastra Scientific Advisory Board Memberawarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment

Cellastra prepares for  clinical study in burn injury

                                           READ MORE